DrugPatentWatch Database Preview
RYZODEG 70/30 Drug Profile
» See Plans and Pricing
Summary for Tradename: RYZODEG 70/30
Recent Clinical Trials for RYZODEG 70/30
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Novo Nordisk A/S | N/A |
Recent Litigation for RYZODEG 70/30
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| NOVO NORDISK INC. v. SANDOZ INC. | 2020-06-04 |
| SMITH v. NOVO NORDISK INC. | 2016-08-08 |
Company Disclosures: US Patents for RYZODEG 70/30
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Novo Nordisk A/S (Bagsvaerd, DK) | 2016-06-20 | DISCN | company | |
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Novo Nordisk A/S (Bagsvaerd, DK) | 2021-01-05 | DISCN | company | |
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Novo Nordisk A/S (Bagsvaerd, DE) | 2023-08-05 | DISCN | company | |
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Novo Nordiks A/S (Bagsvaerd, DK) | 2024-10-21 | DISCN | company | |
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Novo Nordisk A/S (Bagsvaerd, DK) | 2021-01-05 | DISCN | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for RYZODEG 70/30
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313 | 001 | 2016-03-07 | Start Trial | Corning Incorporated (Corning, NY) | 2031-10-25 | DISCN | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for RYZODEG 70/30
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2275439 | Start Trial |
| Canada | 2584760 | Start Trial |
| European Patent Office | 2287184 | Start Trial |
| European Patent Office | 2275439 | Start Trial |
| Japan | 2009502273 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RYZODEG 70/30
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C02107069/01 | Switzerland | Start Trial | PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013 |
| C201300035 | Spain | Start Trial | PRODUCT NAME: INSULINA DEGLUDEC; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF FIRST AUTHORISATION IN EEA: 20130121 |
| 1390036-0 | Sweden | Start Trial | PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121 |
| 472 | Finland | Start Trial | |
| 13C0035 | France | Start Trial | PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
